Table 1.
Clinicopathological characteristics of the DLBCL cases in GSE10846 and TCGA datasets
| Characteristic | GSE10846 | TCGA | ||
|---|---|---|---|---|
| All GSE10846 (n = 412) | Training cohort (n = 330) | Testing cohort (n = 82) | Validation cohort (n = 47) | |
| Gender | ||||
| Male | 222 (53.9%) | 173 (52.4%) | 49 (59.8%) | 26 (55%) |
| Female | 172 (41.7%) | 141 (42.7%) | 31 (37.8%) | 21 (45%) |
| NA | 18 (4.3%) | 16 (4.8%) | 2 (2.4%) | |
| Age (year) | ||||
| ≤ 60 | 188 (45.6%) | 144 (43.6%) | 44 (53.7%) | 26 (55%) |
| > 60 | 224 (54.4%) | 186 (56.4%) | 38 (46.3%) | 21 (45%) |
| ECOG-PS | ||||
| < 2 | 296 (71.8%) | 239 (72.4%) | 57 (69.5%) | |
| ≥ 2 | 93 (22.6%) | 75 (22.7%) | 18 (22.0%) | |
| NA | 24 (5.8%) | 17 (5.2%) | 7 (8.5%) | |
| (COO) Subtypes | ||||
| ABC | 167 (40.5%) | 132 (40.0%) | 35 (42.6%) | |
| GCB | 182 (44.2%) | 148 (44.8%) | 34 (41.4%) | |
| NA | 63 (15.3%) | 50 (15.2%) | 13 (15.9%) | |
| LDH level | ||||
| Normal | 173 (42.0%) | 134 (40.6%) | 39 (47.6%) | |
| Elevated | 177 (43.0%) | 143 (43.3%) | 34 (41.5%) | |
| NA | 62 (15.0%) | 53 (16.1%) | 9 (11.0%) | |
| Ann Arbor stage | ||||
| I–II | 188 (45.6%) | 147 (44.5%) | 41 (50.0%) | |
| III–IV | 217 (52.7%) | 176 (53.3%) | 41 (50.0%) | |
| NA | 7 (1.7%) | 7 (2.1%) | ||
| Extranodal sites | ||||
| < 2 | 297 (72.1%) | 236 (71.5%) | 61 (74.4%) | |
| ≥ 2 | 23 (5.6%) | 19 (5.8%) | 4 (4.9%) | |
| NA | 92 (22.3%) | 75 (22.7%) | 17 (20.7%) | |
The GSE10846 dataset was randomly divided (4:1 ratio) into a training cohort (n = 330) and a testing cohort (n = 82). ECOG Eastern Cooperative Oncology Group, PS performance status, LDH lactate dehydrogenase, COO cell-of-origin, ABC activated B-cell-like, GCB germinal center B-cell-like, NA not available